CSL Earnings Slashed Amidst Vaccination Decline
CSL has significantly revised its earnings and revenue forecasts due to a decline in US vaccination rates.
According to the company, this decline coincides with the decision to shelve plans for the demerger of its Seqirus vaccines business.
Additionally, CSL faces a potential board spill following a second consecutive year of shareholder rejection of the company's remuneration report.
- A 12 per cent drop in US vaccination rates is anticipated during the upcoming northern hemisphere winter.
- The announcement was made ahead of CSL's annual general meeting.
No specific statement from the company is provided.
Author's summary: CSL revises earnings due to vaccination decline.
More News
- In Anish Kapoor’s Hands, an Offshore Gas Rig Became a Call for Climate Accountability
- From decline to renewal: Why leadership still matters
- Australian government bans Dutch volleyball rapist
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Venture Capital, Moonshots, and AI: The 2025 Tech Soap Opera
- Australian government bans Dutch volleyball rapist
- Comment | A spate of dealer anniversaries offers hope amid art market doomerism
- How businesses can implement Zero Waste practices
- The AI Gender Gap Paradox (SSIR)
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids